Scilex Holding Company Interest Income, Debt Securities, Held-to-maturity
Scilex Holding Company (SCLX) reported Interest Income, Debt Securities, Held-to-maturity of $664.97 thousand for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-04.
Discontinued › Expense Statement › Operating Expenses
us-gaap:InterestAndDividendIncomeSecuritiesHeldToMaturity · last filed 2022-11-04
- Scilex Holding Company interest income, debt securities, held-to-maturity for the quarter ending 2022-09-30 was $459.11K, a 25491.64% increase year-over-year.
- Scilex Holding Company interest income, debt securities, held-to-maturity for the quarter ending 2022-06-30 was $203.90K, a 677.90% increase year-over-year.
- Scilex Holding Company interest income, debt securities, held-to-maturity for the quarter ending 2022-03-31 was $1.96K, a 89.93% decline year-over-year.
- Scilex Holding Company interest income, debt securities, held-to-maturity for the quarter ending 2021-12-31 was $2.73K.
- Scilex Holding Company interest income, debt securities, held-to-maturity for fiscal 2021 was $30.74K.
| Period end | Interest Income, Debt Securities, Held-to-maturity 3 month | Interest Income, Debt Securities, Held-to-maturity 6 month | Interest Income, Debt Securities, Held-to-maturity 9 month | Interest Income, Debt Securities, Held-to-maturity 12 month |
|---|---|---|---|---|
| 2022-09-30 | $459.11K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | $663.02K derived: sum of 2 quarters · filed 2022-11-04 | $664.97K 10-Q · filed 2022-11-04 | $667.71K derived: sum of 4 quarters · filed 2022-11-04 |
| 2022-06-30 | $203.90K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $205.86K 10-Q · filed 2022-08-12 | $208.59K derived: sum of 3 quarters · filed 2022-08-12 | $210.39K derived: sum of 4 quarters · filed 2022-11-04 |
| 2022-03-31 | $1.96K 10-Q · filed 2022-05-16 | $4.69K derived: sum of 2 quarters · filed 2022-05-16 | $6.48K derived: sum of 3 quarters · filed 2022-11-04 | $32.69K derived: sum of 4 quarters · filed 2022-11-04 |
| 2021-12-31 | $2.73K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $4.53K derived: sum of 2 quarters · filed 2022-11-04 | $30.74K derived: sum of 3 quarters · filed 2022-11-04 | $30.74K 10-K · filed 2022-02-24 |
| 2021-09-30 | $1.79K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | $28.01K derived: sum of 2 quarters · filed 2022-11-04 | $28.01K 10-Q · filed 2022-11-04 | |
| 2021-06-30 | $26.21K 10-Q/A · filed 2021-08-24 | $26.21K 10-Q · filed 2022-08-12 | ||
| 2021-03-31 | $19.42K 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |